Zacks Investment Research upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a hold rating to a buy rating in a research report sent to investors on Tuesday, Zacks.com reports. They currently have $21.00 price objective on the biotechnology company’s stock.
According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
Several other research analysts also recently weighed in on the company. ValuEngine upgraded Zynerba Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, May 17th. Mizuho boosted their target price on Microchip Technology from $95.00 to $100.00 and gave the stock a buy rating in a research note on Thursday, May 9th. Citigroup upgraded Atara Biotherapeutics from a sell rating to a neutral rating and boosted their target price for the stock from $23.00 to $24.00 in a research note on Monday, June 3rd. Wedbush boosted their target price on Workday from $209.00 to $211.00 and gave the stock a neutral rating in a research note on Wednesday, May 29th. Finally, BidaskClub downgraded Vertex Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $41.86.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.48) by $0.04. On average, equities research analysts anticipate that Atara Biotherapeutics will post -5.54 earnings per share for the current year.
In other Atara Biotherapeutics news, insider Joe Newell sold 1,500 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the completion of the transaction, the insider now owns 62,998 shares of the company’s stock, valued at $2,204,930. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 7,800 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $24.61, for a total value of $191,958.00. Following the transaction, the chief executive officer now directly owns 332,243 shares of the company’s stock, valued at approximately $8,176,500.23. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,950 shares of company stock worth $641,147. Company insiders own 7.00% of the company’s stock.
Several institutional investors have recently made changes to their positions in ATRA. FMR LLC raised its holdings in shares of Atara Biotherapeutics by 21.7% during the first quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after acquiring an additional 1,143,787 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Atara Biotherapeutics by 53.8% in the first quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock valued at $76,237,000 after purchasing an additional 671,216 shares in the last quarter. Norges Bank purchased a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $20,648,000. Federated Investors Inc. PA grew its position in shares of Atara Biotherapeutics by 47.6% in the first quarter. Federated Investors Inc. PA now owns 903,307 shares of the biotechnology company’s stock valued at $35,906,000 after purchasing an additional 291,207 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Atara Biotherapeutics by 107.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 474,973 shares of the biotechnology company’s stock valued at $16,500,000 after purchasing an additional 245,832 shares in the last quarter.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: Certificate of Deposit (CD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.